Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 755-762

  Mbikay, Majambu ^a,b,c   Sirois, Francine ^a,c   Simoes, Sonia ^a   Mayne, Janice ^b   Chrétien, Michel ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Cholesterol; Hepatocytes; Low density lipoprotein receptor; Proprotein convertase; Quercetin; Sortilin

Indexed keywords

FLAVONOID; HYPOCHOLESTEROLEMIC AGENT; ISOQUERCITRIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; SUBTILISIN; UNCLASSIFIED DRUG;

ANTICHOLESTEROLEMIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL ANIMAL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID TRANSPORT; LIPOPROTEIN SECRETION; LIVER CELL; LIVER CLEARANCE; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 84907095078     PISSN: None     EISSN: 22115463     Source Type: Journal    
DOI: 10.1016/j.fob.2014.08.003     Document Type: Article

References (48)

1. Bittner V. Non-high-density lipoprotein cholesterol and cardiovascular disease. Curr. Opin. Lipidol. 2003, 14(4):367-371.
2. Brown M.S., Goldstein J.L. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J. Clin. Invest. 1983, 72(3):743-747.
3. Mbikay M., Mayne J., Chretien M. Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions. J. Diabetes 2013, 5(4):391-405.
4. Seidah N.G. The proprotein convertases, 20years later. Methods Mol. Biol. 2011, 768:23-57.
5. Chretien M. My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. Biochem. Cell Biol. 2012, 90(6):750-768.
6. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(3):928-933.
7. Mayne J., Dewpura T., Raymond A., Bernier L., Cousins M., Ooi T.C., Davignon J., Seidah N.G., Mbikay M., Chretien M. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin. Chem. 2011, 57(10):1415-1423.
8. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 2009, 50(Suppl.):S172-S177.
9. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34(2):154-156.
10. Naoumova R.P., Tosi I., Patel D., Neuwirth C., Horswell S.D., Marais A.D., van Heyningen C., Soutar A.K. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 2005, 25(12):2654-2660.
11. Abifadel M., Guerin M., Benjannet S., Rabes J.P., Le Goff W., Julia Z., Hamelin J., Carreau V., Varret M., Bruckert E., et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 2012, 223(2):394-400.
12. Delahoy P.J., Magliano D.J., Webb K., Grobler M., Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin. Ther. 2009, 31(2):236-244.
13. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2004, 24(8):1454-1459.
14. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(15):5374-5379.
15. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 2006, 26(5):1094-1100.
16. Pisciotta L., Sallo R., Rabacchi C., Wunsch A., Calandra S., Bertolini S. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr. Metab. Cardiovasc. Dis. 2012, 22(10):831-835.
17. Chre´tien M., Seidah N.G., Basak A., Mbikay M. Proprotein convertases as therapeutic targets. Expert Opin. Ther. Targets 2008, 12(10):1289-1300.
18. Hooper A.J., Burnett J.R. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin. Biol. Ther. 2013, 13(3):429-435.
19. Seidah N.G. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr. Pharm. Des. 2013, 19(17):3161-3172.
20. Mukherjee P.K. Plant products with hypocholesterolemic potentials. Adv. Food Nutr. Res. 2003, 47:277-338.
21. Romano B., Pagano E., Montanaro V., Fortunato A.L., Milic N., Borrelli F. Novel insights into the pharmacology of flavonoids. Phytother. Res. 2013, 27(11):1588-1596.
22. Kelly G.S. Quercetin Monograph. Altern. Med. Rev. 2011, 16(2):172-194.
23. Juzwiak S., Wojcicki J., Mokrzycki K., Marchlewicz M., Bialecka M., Wenda-Rozewicka L., Gawronska-Szklarz B., Drozdzik M. Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol. Rep. 2005, 57(5):604-609.
24. Kamada C., da Silva E.L., Ohnishi-Kameyama M., Moon J.H., Terao J. Attenuation of lipid peroxidation and hyperlipidemia by quercetin glucoside in the aorta of high cholesterol-fed rabbit. Free Radic. Res. 2005, 39(2):185-194.
25. Rivera L., Moron R., Sanchez M., Zarzuelo A., Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity 2008, 16(9):2081-2087.
26. Hua X., Yokoyama C., Wu J., Briggs M.R., Brown M.S., Goldstein J.L., Wang X. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(24):11603-11607.
27. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89(3):331-340.
28. Zeng L., Liao H., Liu Y., Lee T.S., Zhu M., Wang X., Stemerman M.B., Zhu Y., Shyy J.Y. Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells: a novel role of SREBP in regulating cholesterol metabolism. J. Biol. Chem. 2004, 279(47):48801-48807.
29. Chen X.W., Wang H., Bajaj K., Zhang P., Meng Z.X., Ma D., Bai Y., Liu H.H., Adams E., Baines A., et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. eLife 2013, 2:e00444.
30. Gustafsen C., Kjolby M., Nyegaard M., Mattheisen M., Lundhede J., Buttenschon H., Mors O., Bentzon J.F., Madsen P., Nykjaer A., et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab. 2014, 19(2):310-318.
31. Gouni-Berthold I., Berthold H.K., Gylling H., Hallikainen M., Giannakidou E., Stier S., Ko Y., Patel D., Soutar A.K., Seedorf U., et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 2008, 198(1):198-207.
32. Mayne J., Dewpura T., Raymond A., Cousins M., Chaplin A., Lahey K.A., Lahaye S.A., Mbikay M., Ooi T.C., Chretien M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008, 7:22.
33. Davalos A., Fernandez-Hernando C., Cerrato F., Martinez-Botas J., Gomez-Coronado D., Gomez-Cordoves C., Lasuncion M.A. Red grape juice polyphenols alter cholesterol homeostasis and increase LDL-receptor activity in human cells in vitro. J. Nutr. 2006, 136(7):1766-1773.
34. Li H., Dong B., Park S.W., Lee H.S., Chen W., Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 2009, 284(42):28885-28895.
35. Dong B., Wu M., Li H., Kraemer F.B., Adeli K., Seidah N.G., Park S.W., Liu J. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 2010, 51(6):1486-1495.
36. Li H., Liu J. The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells. Biochem. J. 2012, 443(3):757-768.
37. Casaschi A., Wang Q., Dang K., Richards A., Theriault A. Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin: potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. Lipids 2002, 37(7):647-652.
38. Strong A., Ding Q., Edmondson A.C., Millar J.S., Sachs K.V., Li X., Kumaravel A., Wang M.Y., Ai D., Guo L., et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J. Clin. Invest. 2012, 122(8):2807-2816.
39. Kjolby M., Andersen O.M., Breiderhoff T., Fjorback A.W., Pedersen K.M., Madsen P., Jansen P., Heeren J., Willnow T.E., Nykjaer A. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010, 12(3):213-223.
40. Linsel-Nitschke P., Heeren J., Aherrahrou Z., Bruse P., Gieger C., Illig T., Prokisch H., Heim K., Doering A., Peters A., et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 2010, 208(1):183-189.
41. Musunuru K., Strong A., Frank-Kamenetsky M., Lee N.E., Ahfeldt T., Sachs K.V., Li X., Li H., Kuperwasser N., Ruda V.M., et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010, 466(7307):714-719.
42. Thaker A.M., Frishman W.H. Sortilin: the mechanistic link between genes, cholesterol, and coronary artery disease. Cardiol. Rev. 2014, 22(2):91-96.
43. Moon J., Lee S.M., Do H.J., Cho Y., Chung J.H., Shin M.J. Quercetin up-regulates LDL receptor expression in HepG2 cells. Phytother. Res. 2012, 26(11):1688-1694.
44. Cermak R., Landgraf S., Wolffram S. The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J. Nutr. 2003, 133(9):2802-2807.
45. Reinboth M., Wolffram S., Abraham G., Ungemach F.R., Cermak R. Oral bioavailability of quercetin from different quercetin glycosides in dogs. Br. J. Nutr. 2010, 104(2):198-203.
46. Paulke A., Eckert G.P., Schubert-Zsilavecz M., Wurglics M. Isoquercitrin provides better bioavailability than quercetin: comparison of quercetin metabolites in body tissue and brain sections after six days administration of isoquercitrin and quercitrin. Pharmazie 2012, 67:991-996.
47. Valentova K., Vrba J., Bancirova M., Ulrichova J., Kren V. Isoquercitrin: pharmacology, toxicology, and metabolism. Food Chem. Toxicol. 2014, 68:267-282.
48. Omar K., Grant M.H., Henderson C., Watson D.G. The complex degradation and metabolism of quercetin in rat hepatocyte incubations. Xenobiotica 2014, 1-9. 10.3109/00498254.2014.932032.